Literature DB >> 15220415

Exchanging the yellow fever virus envelope proteins with Modoc virus prM and E proteins results in a chimeric virus that is neuroinvasive in SCID mice.

Nathalie Charlier1, Richard Molenkamp, Pieter Leyssen, Jan Paeshuyse, Christian Drosten, Marcus Panning, Erik De Clercq, Peter J Bredenbeek, Johan Neyts.   

Abstract

A chimeric flavivirus infectious cDNA was constructed by exchanging the premembrane (prM) and envelope (E) genes of the yellow fever virus vaccine strain 17D (YF17D) with the corresponding genes of Modoc virus (MOD). This latter virus belongs to the cluster of the "not-known vector" flaviviruses and is, unlike YF17D, neuroinvasive in SCID mice. Replication of in vitro-transcribed RNA from this chimeric flavivirus was shown by [(3)H]uridine labeling and RNA analysis. Expression of the MOD prM and E proteins was monitored by radioimmunoprecipitation and revealed that the MOD proteins were correctly and efficiently produced from the chimeric precursor protein. The MOD E protein was shown to be N-linked glycosylated, whereas prM, as predicted from the genome sequence, did not contain N-linked carbohydrates. In Vero cells, the chimeric virus replicated with a similar efficiency as the parental viruses, although it formed smaller plaques than YF17D and MOD. In SCID mice that had been infected intraperitoneally with the chimeric virus, the viral load increased steadily until death. The MOD/YF virus, like MOD from which it had acquired the prM and E structural proteins, but unlike YF, proved neuroinvasive in SCID mice. Animals developed neurological symptoms about 15 days after inoculation and died shortly thereafter. The distribution of MOD/YF RNA in the brain of infected mice was similar to that observed in MOD-infected mice. The observations provide compelling evidence that the determinants of neuroinvasiveness of flaviviruses are entirely located in the envelope proteins prM and E.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15220415      PMCID: PMC434118          DOI: 10.1128/JVI.78.14.7418-7426.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Chimeric Langat/Dengue viruses protect mice from heterologous challenge with the highly virulent strains of tick-borne encephalitis virus.

Authors:  A G Pletnev; G G Karganova; T I Dzhivanyan; V A Lashkevich; M Bray
Journal:  Virology       Date:  2000-08-15       Impact factor: 3.616

2.  trans-Complementation of yellow fever virus NS1 reveals a role in early RNA replication.

Authors:  B D Lindenbach; C M Rice
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

3.  Antigenic variants of yellow fever virus with an altered neurovirulence phenotype in mice.

Authors:  K D Ryman; H Xie; T N Ledger; G A Campbell; A D Barrett
Journal:  Virology       Date:  1997-04-14       Impact factor: 3.616

4.  A novel model for the study of the therapy of flavivirus infections using the Modoc virus.

Authors:  P Leyssen; C Drosten; H Schmitz; J Neyts
Journal:  Virology       Date:  2001-01-05       Impact factor: 3.616

Review 5.  West Nile virus vaccine.

Authors:  T P Monath; J Arroyo; C Miller; F Guirakhoo
Journal:  Curr Drug Targets Infect Disord       Date:  2001-05

6.  Genetic determinants responsible for acquisition of dengue type 2 virus mouse neurovirulence.

Authors:  M Bray; R Men; I Tokimatsu; C J Lai
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

7.  Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties.

Authors:  T J Chambers; A Nestorowicz; P W Mason; C M Rice
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

8.  Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.

Authors:  F Guirakhoo; K Pugachev; J Arroyo; C Miller; Z-X Zhang; R Weltzin; K Georgakopoulos; J Catalan; S Ocran; K Draper; T P Monath
Journal:  Virology       Date:  2002-06-20       Impact factor: 3.616

9.  A stable full-length yellow fever virus cDNA clone and the role of conserved RNA elements in flavivirus replication.

Authors:  Peter J Bredenbeek; Engbert A Kooi; Brett Lindenbach; Nicolette Huijkman; Charles M Rice; Willy J M Spaan
Journal:  J Gen Virol       Date:  2003-05       Impact factor: 3.891

10.  Neuroadapted yellow fever virus 17D: determinants in the envelope protein govern neuroinvasiveness for SCID mice.

Authors:  Michael Nickells; Thomas J Chambers
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

View more
  14 in total

1.  Replacement of the 3' untranslated variable region of mosquito-borne dengue virus with that of tick-borne Langat virus does not alter vector specificity.

Authors:  Ebenezer Tumban; Dana N Mitzel; Nyree E Maes; Christopher T Hanson; Stephen S Whitehead; Kathryn A Hanley
Journal:  J Gen Virol       Date:  2011-01-07       Impact factor: 3.891

2.  Recovery of West Nile Virus Envelope Protein Domain III Chimeras with Altered Antigenicity and Mouse Virulence.

Authors:  Alexander J McAuley; Maricela Torres; Jessica A Plante; Claire Y-H Huang; Dennis A Bente; David W C Beasley
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

3.  Replacement of conserved or variable sequences of the mosquito-borne dengue virus 3' UTR with homologous sequences from Modoc virus does not change infectivity for mosquitoes.

Authors:  Ebenezer Tumban; Nyree E Maes; Erin E Schirtzinger; Katherine I Young; Christopher T Hanson; Stephen S Whitehead; Kathryn A Hanley
Journal:  J Gen Virol       Date:  2012-12-19       Impact factor: 3.891

4.  Auditory function analysis in immunodeficient STAT1 knock-out mice: Considerations for viral infection models.

Authors:  Tomoharu Suzuki; Junki Maruyama; Rebecca Cook; Shinji Urata; Slobodan Paessler; Tomoko Makishima
Journal:  Neurosci Lett       Date:  2020-10-15       Impact factor: 3.046

5.  An analogue of the antibiotic teicoplanin prevents flavivirus entry in vitro.

Authors:  Tine De Burghgraeve; Suzanne J F Kaptein; Nilda V Ayala-Nunez; Juan A Mondotte; Boris Pastorino; Svetlana S Printsevskaya; Xavier de Lamballerie; Michael Jacobs; Maria Preobrazhenskaya; Andrea V Gamarnik; Jolanda M Smit; Johan Neyts
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

6.  Chimeric Zika viruses containing structural protein genes of insect-specific flaviviruses cannot replicate in vertebrate cells due to entry and post-translational restrictions.

Authors:  Chandra S Tangudu; Jermilia Charles; Daniel Nunez-Avellaneda; Alissa M Hargett; Aaron C Brault; Bradley J Blitvich
Journal:  Virology       Date:  2021-03-26       Impact factor: 3.513

Review 7.  Insect-specific flaviviruses: a systematic review of their discovery, host range, mode of transmission, superinfection exclusion potential and genomic organization.

Authors:  Bradley J Blitvich; Andrew E Firth
Journal:  Viruses       Date:  2015-04-10       Impact factor: 5.048

8.  Substitution of the premembrane and envelope protein genes of Modoc virus with the homologous sequences of West Nile virus generates a chimeric virus that replicates in vertebrate but not mosquito cells.

Authors:  Rungrat Saiyasombat; Jimena Carrillo-Tripp; Wyatt Allen Miller; Peter J Bredenbeek; Bradley J Blitvich
Journal:  Virol J       Date:  2014-08-24       Impact factor: 4.099

Review 9.  Flaviviral NS4b, chameleon and jack-in-the-box roles in viral replication and pathogenesis, and a molecular target for antiviral intervention.

Authors:  Joanna Zmurko; Johan Neyts; Kai Dallmeier
Journal:  Rev Med Virol       Date:  2015-04-01       Impact factor: 6.989

10.  First international external quality assessment study on molecular and serological methods for yellow fever diagnosis.

Authors:  Cristina Domingo; Camille Escadafal; Leonid Rumer; Jairo A Méndez; Paquita García; Amadou A Sall; Anette Teichmann; Oliver Donoso-Mantke; Matthias Niedrig
Journal:  PLoS One       Date:  2012-05-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.